DGAP-News: Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

PRESS RELEASE
07 November 2018

/

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon's proprietary immunoassay technology to be incorporated into
Quanterix' Simoa Planar Immunoassay products

Heidelberg, Germany and Cambridge, UK, 07 November 2018 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provides Quanterix access to Expedeon's breadth of immunoassay technologies for application to their ultrasensitive Simoa Immunoassay offerings.

The agreement with Quanterix will provide non-exclusive access to Expedeon's CaptSure(TM) immunoassay technology for single target analysis (singleplex), as well as the rapid Lightning-Link^(R) conjugation technology for antibody labelling.

Dr Heikki Lanckreit, CEO and CSO of Expedeon, said: "This agreement brings together two companies that are pushing new boundaries with their respective technologies. Expedeon is a leader in the development of immunoassay technologies that speed up life science research. Combining our technologies with those of Quanterix will provide the industry with unmatched new capabilities for protein discovery. We are extremely excited about this new venture, and look forward to examining further opportunities with Quanterix as the partnership expands."

Unlike conventional immunoassay technologies, the CaptSure(TM) system provides a universal base onto which antibodies can be immobilised. In conjunction with Lightning-Link^(R) technology it provides for a robust, reliable and faster immunoassay system, with the ability to deploy assay content across different test platforms.

"We are pleased to be able to incorporate Expedeon technologies in our newest product offerings, providing additional flexibility and performance to researchers utilizing our Simoa technology to measure digital biomarkers and fuel new discoveries," said Kevin Hrusovsky, Quanterix' CEO, President and Chairman.

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Phone: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###